Klogene and Boston University Scientists are First to use CRISPR for Activation of the Life Extension and Cognition …PR Newswire (press release)BOSTON, Jan. 22, 2018 /PRNewswire/ — In a paper published today in Journal of Molecular Neuroscience, sci… Continue reading
Drug Target ReviewSynthetic horsepox virus could lead to more effective smallpox vaccineDrug Target ReviewDr Evans hopes the research will contribute to informed discussions relating to the potential applications of synthetic biology for the benefit of… Continue reading
Sterne, Kessler, Goldstein & Fox Elects Five New DirectorsIPWatchdog.com… International Trade Commission investigations under §337, evaluating patent portfolios, drafting patent applications, and prosecuting interferences. He also manages the pre… Continue reading
Sterne, Kessler, Goldstein & Fox Elects Five New DirectorsIPWatchdog.com… International Trade Commission investigations under §337, evaluating patent portfolios, drafting patent applications, and prosecuting interferences. He also manages the pre… Continue reading
Eureka Therapeutics Closes $60 Million in Series D Financing to Advance Proprietary ARTEMIS™ T Cell Receptor …Business Wire (press release)This financing represents an important validation of our strategy, and provides us the resources to advance our… Continue reading
Medical XpressNot just a stem cell marker – Medical XpressMedical XpressThe protein CD34 is predominantly regarded as a marker of blood-forming stem cells but it helps with migration to the bone marrow too.and more »… Continue reading
Endpoints News |
Celgene is buying cancer drugmaker Juno Therapeutics for $9 billion
Markets Insider One challenge these therapies still face is how toxic they can be. CAR–T’s side effects can be deadly. In May 2017, Kite disclosed that one person had died in a clinical trial for its late-stage CAR–T therapy from cerebral edema, a condition in which … Celgene to buy Juno for $9 billion to boost CAR–T expertiseReuters UPDATED: Celgene bags CAR–T player Juno in $9B buyout as biotech M&A suddenly explodesEndpoints News Shares of biotech Juno, already up 50% on deal hopes, skyrocket on actual Celgene $9 billion offerCNBC Business Wire (press release) –Financial Times all 128 news articles » |